Emcure, Glenmark arm, 3 others line up Rs 7000 crore IPOs

Khyati Shah01 Jun, 2021Business

Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the second consecutive year as several pharma and life sciences companies are lined up to tap the equity markets through IPOs over the next few months, according to investment bankers.Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research.